UNSPSC 51392224: Lofexidine hydrochloride

This classification denotes an alpha-adrenergic agonist with the molecular formula C11H12Cl2N2O.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier V47G1SDI1B, chemically known as 2-imidazoline, 2-(1-(2,6-dichlorophenoxy)ethyl)-, monohydrochloride but more generally known as lofexidine hydrochloride, which bears US NIH Compound Identifier 30667. European Medicines Agency schedules Lofexidine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02966MIG.

Most nations, for tariff and trade purposes, schedule lofexidine hydrochloride under HS 29332990. As of Q4 2014, LOFEXIDINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Lofexidine hydrochloride bears US NLM identifiers UMLS ID C0771049 and NCI Concept Code C87581. SMILES: CC(C1=NCCN1)OC2C(CCCC2CL)CL.CL.

UNSPSC 51392224 Lofexidine hydrochloride is a Commodity code that in practice encompasses pharmaceutical products for addiction treatment and emergency response, though recent state and local opportunities show minimal direct activity under this specific code. The Seminole County, Florida opportunity tagged to this code actually solicits naloxone and drug deactivation systems rather than lofexidine specifically, indicating a mismatch between the code's nominal scope and what jurisdictions are actually purchasing. State and local governments using this code tier appear focused on opioid crisis response and harm-reduction pharmaceuticals delivered through health departments and community health programs, with procurement structured around regular replenishment cycles and quarterly delivery schedules. Issuing bodies include county health systems and state health and human services agencies; the two recent records show Seminole County (a Florida county) and the Texas Health and Human Services Commission (a state health agency). Neither opportunity explicitly names lofexidine as a requirement.

Geographic activity is concentrated in the South and Southwest based on the available records. Seminole County's IFB (IFB60459723LAS, due July 26, 2023, though posted in June 2026 with a conflicting 2023 deadline) sought 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a two-year initial term plus one-year renewal option. The Texas Health and Human Services Commission issued an RFI (HHS0017013, due April 3, 2026) to explore direct-to-manufacturer pharmacy contracting capability for a Therapeutic Pharmacy Initiative, framing future procurement strategy rather than an immediate purchase. The code shows little current momentum; bidders should note that naloxone and lofexidine are distinct pharmaceutical products addressing opioid response through different mechanisms, and state-local procurement under this code may be sparse or tagged inconsistently across jurisdictions.